

abrdn Medical Science Innovation Portfolio, Series 9

Investment Objective

The abrdn Medical Science Innovation Portfolio, Series 8 (trust) seeks to maximize total return through capital appreciation.

Key Considerations


- **Growth Potential from Innovation:** Seeks to offer attractive growth opportunities from the advances that may drive the future of the healthcare sector.
- **Portfolio Founded on Healthcare Expertise:** Guggenheim, with the assistance of abrdn, selects portfolio holdings through a unique combination of fundamental research and extensive expertise in the healthcare industry.
- **Capitalize on Demographic Trends:** Guggenheim believes an aging population and increases in chronic conditions, such as obesity, diabetes and cancer, may fuel demand for innovative healthcare solutions.

Past performance is no guarantee of future results. There is no guarantee that these trends and projections will continue or come to fruition and they are subject to change.


Portfolio Allocation

Breakdown and weightings are as of 11.20.2024 and subject to change.

CAPITALIZATION BREAKDOWN



STYLE BREAKDOWN



Capitalize on Next-Gen Healthcare Growth Opportunities

Propelled by innovation and changing demographics, the healthcare industry may be entering an age that may offer opportunities to extend and enhance the quality of human lives. In many areas of the healthcare sector, accelerated research, funding, use of technology applications, and faster regulatory approvals are spurring the pace and volume of medical advances and opening new investment opportunities, such as gene therapy, personalized medicine and cell-based therapies. Guggenheim believes demographic shifts of an aging population and increases in chronic health issues may also act as tailwinds to drive new opportunities in healthcare.

To provide exposure to this exciting growth potential, Guggenheim has partnered with abrdn Inc. (“abrdn”) to develop the **abrdn Medical Science Innovation Portfolio**, which seeks to offer access to innovative medical science companies, companies considered to be developing novel products to address medical needs. abrdn has a team of leading healthcare management professionals that combines a top-down perspective based on deep knowledge of the healthcare sector with bottoms-up fundamental research to potentially identify some of the most promising opportunities in a dynamic market. The abrdn Medical Science Innovation Portfolio seeks to maximize total return by investing in innovative companies that may be able to capitalize from the key trends currently driving healthcare.

Key Themes


The portfolio seeks to offer exposure to ten identified segments of the market where Guggenheim and abrdn believe significant innovation and growth are occurring:

Genetic Medicine & Rare Disease The use of genes to treat rare diseases by inserting functional or healthy copies of a gene to circumvent the function of a mutated gene that is dysfunctional.	Neurological Disorders Diseases of the brain and central nervous system remain a challenge where current treatment options leave room for improvement. Unmet need exists for those suffering from major depression, migraines, Alzheimers and Parkinsons.
Special Situations: Global ADRs Global healthcare firms that are leaders in innovation with American Depository Receipts (ADRs) traded in the U.S.	Targeted Oncology Treatments that focus on cancer cells with less harm to normal/healthy cells. A dominant trend is the development of therapies personalized to each individual's specific disease, often using genomic testing.
Autoimmune Disorders These disorders occur when the immune system mistakenly attacks and kills the body's own cells. New advances are exploring targeted and personalized medicine to treat these disorders.	Advanced Devices & Equipment Implants, consumables, monitoring equipment and wearables used in the diagnosis and treatment of diseases are improving patient outcomes and lowering overall healthcare costs.
Diagnostics A focus on diagnosis and therapy of disease.	Digital & Personal Health Monitoring Leverage technology to monitor and manage chronic patients.
Core Holdings A health care company Guggenheim and abrdn considered to hold a strong competitive position in its area of focus with strong growth opportunities.	Aging Population The percentage of Americans 65+ is expected to increase 47% by 2050 ¹ —this demographic will likely have more healthcare needs.

Source: Guggenheim Investments/abrdn. ¹ Population Reference Bureau, “Fact Sheet: Aging in the United States,” January 9, 2024.







Security Selection Process

In selecting the innovative healthcare companies to be included in the portfolio, Guggenheim, with the assistance of abrdn, starts with a universe of companies in the medical sciences industry, which include healthcare companies, as well as those whose business is involved in researching, developing and producing medical, pharmaceutical or biotechnology products, supplies or equipment.



abrdn offers investment expertise across all key asset classes, regions and markets so that clients can capture investment potential wherever it arises. It operates in over 30 locations worldwide, ensuring first-hand insight into companies, industries and markets. As of September 30, 2024, abrdn managed 493.9 billion in assets on behalf of individuals, funds, governments, pension funds, insurer, companies, charities and foundations across 80 countries. The combination of abrdn's research, thematic thinking, and extensive on-the-ground analysis helps abrdn find the most sustainable future-fit investment opportunities globally.

Trends Impacting the Healthcare Industry



2 Clinicaltrials.gov from 181,218 in 2014 to 515,319 as of 11.8.2024. 3 National Institutes of Health National Human Genome Research Institute, "Rare Disease FAQ," 8.16.2024. 4 Population Reference Bureau, "Fact Sheet: Aging in the United States," 1.9.2024. 5 Peter G. Peterson Foundation, "Healthcare Spending will be One-Fifth of the Economy within a Decade," 9.18.2024. 6 "World Obesity Atlas 2024," 3.2024. 7 Statista, "Wearable devices ownership in selected countries as of 3.2024." 8 BioSpace, "U.S. Wearable Medical Devices Market Size to Hit USD 112.67 Bn by 2033," 7.8.2024.

There is no guarantee that the trends and projections noted above will continue or come to fruition and they are subject to change.

PORTFOLIO HOLDINGS

Holdings, breakdown, and weightings are as of 11.20.2024 and subject to change.

Symbol	Company Name
Advanced Devices and Equipment 15.12%	
BDX	Becton Dickinson & Company
COO	Cooper Companies, Inc.
DXCM	Dexcom, Inc.
GKOS	Glaukos Corporation
INSP	Inspire Medical Systems, Inc.
ISRG	Intuitive Surgical, Inc.
PEN	Penumbra, Inc.
SYK	Stryker Corporation
TNDM	Tandem Diabetes Care, Inc.
Aging Population 15.04%	
CI	Cigna Group
CYTK	Cytokinetics, Inc.
ELV	Elevance Health, Inc.
HCA	HCA Healthcare, Inc.
HUM	Humana, Inc.
MCK	McKesson Corporation
MOH	Molina Healthcare, Inc.
THC	Tenet Healthcare Corporation
UNH	UnitedHealth Group, Inc.
Autoimmune Disorders 6.63%	
IMVT	Immunovant, Inc.
INSM	Insmad, Inc.
REGN	Regeneron Pharmaceuticals, Inc.
VRTX	Travere Therapeutics, Inc.
Core Holding 8.37%	
ALC	Alcon AG
LLY	Eli Lilly & Company
TMO	Thermo Fisher Scientific, Inc.
PCVX	Vaxcyte, Inc.
ZTS	Zoetis, Inc.
Diagnostics 4.99%	
ABT	Abbott Laboratories
GEHC	GE HealthCare Technologies, Inc.
GH	Guardant Health, Inc.

Symbol	Company Name
Digital and Personal Health Monitoring 3.26%	
BSX	Boston Scientific Corporation
RMD	ResMed, Inc.
Genetic Medicine & Rare Disease 8.34%	
AMLX	Amylyx Pharmaceuticals, Inc.
ARWR	Arrowhead Pharmaceuticals, Inc.
BMRN	BioMarin Pharmaceutical, Inc.
EWTX	Edgewise Therapeutics, Inc.
RARE	Ultragenyx Pharmaceutical, Inc.
Neurological Disorders 8.28%	
AXSM	Axsome Therapeutics, Inc.
BIIB	Biogen, Inc.
CNTA	Centessa Pharmaceuticals PLC
ITCI	Intra-Cellular Therapies, Inc.
NBIX	Neurocrine Biosciences, Inc.
Special Situations - Global ADRS 14.97%	
ABVX	Abivax SA
ARGX	Argenx SE
ASND	Ascendis Pharma A/S
AZN	AstraZeneca PLC
ICLR	ICON PLC
IMTX	Immatics NV
NAMS	NewAmsterdam Pharma Company NV
NVO	Novo Nordisk A/S
SNY	Sanofi SA
Targeted Oncology 15.00%	
ARVN	Arvinas, Inc.
GERN	Geron Corporation
IDYA	Ideaya Biosciences, Inc.
MRK	Merck & Co, Inc.
MRUS	Merus NV
NUVL	Nuvalent, Inc.
RVMD	REVOLUTION Medicines, Inc.
SMMT	Summit Therapeutics, Inc.
SNDX	Syndax Pharmaceuticals, Inc.

PORTFOLIO SUMMARY

Inception Date	11.21.2024
Termination Date	11.23.2026
Initial Offer Price	\$10.00
Number of Issues	60
Historical Annual Dividend Distribution⁹	\$0.0051
Distributions	25th day of each month commencing on 12.25.2024, if any

SALES CHARGES AND ESTIMATED EXPENSES

The sales charges (S/C) and estimated expenses are based on a \$10 per unit offering price.

	Standard	Fee/Wrap ¹⁰
Deferred S/C ¹¹	2.25%	-
Creation and Development (C&D) Fee	0.50%	0.50%
Total S/C	2.75%	0.50%
Estimated Organization Expenses ¹²	0.67%	0.67%
Estimated Annual Fund Operating Expenses ¹³	0.32%	0.32%

TICKETING INFORMATION - CUSIPS

Cash	40178D723
Reinvest	40178D731
Fee/Cash	40178D749
Fee/Reinvest	40178D756
Ticker	CTMEIX

⁹The Historical Annual Dividend Distribution (HADD) is as of the day prior to trust deposit and subject to change. There is no guarantee the issuers of the securities included in the trust will declare dividends or distributions in the future. The HADD of the securities included in the trust is for illustrative purposes only and is not indicative of the trust's distribution rate. The HADD is the weighted average of the trailing twelve-month distributions paid by the securities included in the portfolio and is reduced to account for the effects of fees and expenses, which will be incurred when investing in the trust. The HADD will vary due to certain factors that may include, but are not limited to, a change in the dividends paid by issuers, a change in trust expenses or the sale or maturity of securities in the portfolio. ¹⁰Fee/Wrap-based accounts will not be assessed the deferred sales charge for eligible purchases and must purchase units with a Fee-based CUSIP. For unit prices other than \$10, percentage of the C&D fee will vary. ¹¹The deferred sales charge will be deducted in three monthly installments on the last business day of months 7 through 9 (June 2025 to August 2025) or upon early redemption. For unit prices other than \$10, percentages of C&D fees, and DSCs will vary but in no event will the maximum sales charge (S/C) exceed the total S/C. Early redemption of units will still cause payment of the DSC. However, an initial sales charge, which is equal to the difference between the maximum S/C and the sum of any remaining deferred S/C charges and C&D, will be charged if the price paid for units exceeds \$10 per unit. ¹²Estimated Organization Expenses are assessed on a fixed dollar amount per unit basis, therefore, actual organization costs may be more or less than estimates. For additional information on organizational costs and potential caps, please see the prospectus. ¹³Trust operating expenses include fees for administration, bookkeeping, the trustee, sponsor, and evaluator. This expense also includes an estimated Trust operating expense based upon an estimated trust size. If the Trust does not reach or falls below the estimated size, the actual amount of the operating expenses may exceed the amount reflected. Please see "Fees and Expenses" in the Trusts prospectus for additional information.

abrdn Medical Science Innovation Portfolio, Series 9 is a Unit Investment Trust.

RISK CONSIDERATIONS: As with all investments, you may lose some or all of your investment in the trust. No assurance can be given that the trust's investment objective will be achieved. The trust also might not perform as well as you expect. This can happen for reasons such as these: • Securities prices can be volatile. The value of your investment may fall over time. Market values of the Trust's securities fluctuate in response to various factors affecting an issuer. Additionally, events such as war, terrorism, natural and environmental disasters and the spread of infectious illnesses or other public health emergencies are impossible to predict and may adversely affect the economy, various markets and issuers, which may negatively impact the performance of the Trust and the Trust's ability to achieve its investment objectives. • The Trust is concentrated in the health care sector. The factors that impact the health care sector will likely have a greater effect on this Trust than on a more broadly diversified trust. • The Trust invests in U.S.-listed foreign securities and in American Depositary Receipts ("ADRs"), which will be more volatile than U.S. securities due to such factors as adverse economic, currency, political,

social or regulatory developments in a country. • The Trust invests in securities issued by small- and mid-capitalization companies, which involve more investment risk to limited product lines, markets or financial resources and may be more vulnerable to adverse general market or economic developments. • The Trust may be susceptible to potential risks through breaches in cybersecurity. • The Trust is subject to risks arising from various operational factors and their service providers. Although the Trust seeks to reduce operational risks through controls and procedures, there is no way to completely protect against such risks. **Please see the Trust prospectus for more complete risk information.**

Unit Investment Trusts are fixed, not actively managed and should be considered as part of a long-term strategy. Investors should consider their ability to invest in successive portfolios, if available, at the applicable sales charge. UITs are subject to annual fund operating expenses in addition to the sales charge. Investors should consult an attorney or tax advisor regarding tax consequences associated with an investment from one series to the next, if available, and with the purchase or sale of units. Guggenheim Funds Distributors, LLC does not offer tax advice.

This material is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation.

Read the trust's prospectus carefully before investing. It contains the trust's investment objectives, risks, charges, expenses and other information, which should be considered carefully before investing. Obtain a prospectus at GuggenheimInvestments.com.

Guggenheim Funds Distributors, LLC

Member FINRA/SIPC

11/2024 UIT-FCT-TMED-009 #63244